Moss, 16.11.2018
Gentian Diagnostics AS announces its results for the third quarter of 2018. The highlights include:
- Total revenues of MNOK 18.4 including a one-off license revenue of MNOK 6.2
- Record sales revenues of MNOK 10.4 for the quarter
- 55% growth in underlying sales revenue compared to 3Q17, 43 % year to date
- Clinical study program for GCAL is progressing according to plan
Please find the report GD-3Q2018-Interim-report.
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525